Oxytocin nasal spray in fibromyalgic patients
- 8 February 2014
- journal article
- research article
- Published by Springer Nature in Rheumatology International
- Vol. 34 (8) , 1047-1052
Abstract
Fibromyalgia is a pain disorder associated with frequent comorbid mood, anxiety, and sleep disorders. Despite the frequent use of a complex, poly-drug pharmacotherapy, treatment for fibromyalgia is of limited efficacy. Oxytocin has been reported to reduce the severity of pain, anxiety, and depression, and improve the quality of sleep, suggesting that it may be useful to treat fibromyalgia. To evaluate this hypothesis, 14 women affected by fibromyalgia and comorbid disorders, assuming a complex pharmacotherapy, were enrolled in a double-blind, crossover, randomized trial to receive oxytocin and placebo nasal spray daily for 3 weeks for each treatment. Order of treatment (placebo–oxytocin or oxytocin–placebo) was randomly assigned. Patients were visited once a week. At each visit, the following instruments were administered: an adverse drug reaction record card, Visual Analog Scale of Pain Intensity, Spielberger State Anxiety Inventory, Zung Self-rating Depression Scale, and SF-12. Women self-registered painkiller assumption, pain severity, and quality of sleep in a diary. Unlikely, oxytocin nasal spray (80 IU a day) did not induce positive therapeutic effects but resulted to be safe, devoid of toxicity, and easy to handle.Keywords
This publication has 24 references indexed in Scilit:
- The Use of Antidepressants in the Long-Term Treatment Should not Improve the Impact of Fibromyalgia on Quality of LifeClinical Practice & Epidemiology in Mental Health, 2013
- The impact of mood, anxiety, and sleep disorders on fibromyalgiaComprehensive Psychiatry, 2012
- Elevated Salivary Levels of Oxytocin Persist More than 7 h after Intranasal AdministrationFrontiers in Neuroscience, 2012
- Improving the Recognition and Diagnosis of FibromyalgiaMayo Clinic Proceedings, 2011
- Pharmacotherapy of fibromyalgiaBest Practice & Research Clinical Rheumatology, 2011
- Oxytocin can hinder trust and cooperation in borderline personality disorderSocial Cognitive and Affective Neuroscience, 2010
- Adjunctive Intranasal Oxytocin Reduces Symptoms in Schizophrenia PatientsBiological Psychiatry, 2010
- A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorderPsychoneuroendocrinology, 2009
- A 12-Item Short-Form Health SurveyMedical Care, 1996
- The american college of rheumatology 1990 criteria for the classification of fibromyalgiaArthritis & Rheumatism, 1990